Fresenius Medical Care Expands Clinical Research Activities

Fresenius Medical Care Expands Clinical Research Activities

Fresenius Medical Care, the world’s largest provider of dialysis products and services, is expanding its clinical research activities. Frenova Renal Research (Frenova), previously a Fresenius Medical Care North America subsidiary, will now offer its services worldwide and will be integrated into the new Global Medical Office headed by Dr. Frank Maddux, Chief Medical Officer.

Frenova offers services for the clinical development of medicines and medical products in the field of kidney research. This offering, previously limited to North America, will now be linked with the corresponding services of Fresenius Medical Care’s Europe, Middle East and Africa (EMEA) and Latin America regions and bundled under Frenova. This will enable the company to draw on a network of more than 550 researchers at over 350 locations.

“Frenova is active at the intersection of clinical research and patient care,” said Dr. Maddux. “No other provider of clinical development services understands the medical needs of people living with kidney disease as well as we do. By making this expertise available worldwide, we will enable a faster, more efficient development of medications and other products. This is an additional, important building block for improving their quality of life.”

About Fresenius Medical Care
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3.4 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,971 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 336,716 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the company provides related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company’s website at


This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Insights You Might Like